Fact Check: The Viral 'GLP-1 Birth Defect' Story

A viral social-media narrative claims GLP-1s are causing birth defects. Here's what the FDA FAERS data actually shows and what the published pregnancy-outcome evidence says.

A series of social-media posts in early 2026 drove a viral narrative that GLP-1 medications are causing a spike in birth defects. The posts typically referenced FDA adverse event reports and included emotionally compelling anecdotes. This source check pulls the actual FDA data and reviews what the published evidence does and does not say about GLP-1 use and pregnancy outcomes.

The honest summary: GLP-1 medications are not recommended during pregnancy, and the prescribing labels have always included cautions about use in women of reproductive potential. Adverse event reports related to pregnancy do exist in the FDA's FAERS database, but adverse event reports are not causal evidence, and the published controlled data on human pregnancy outcomes with GLP-1 exposure remains limited.

What the Prescribing Labels Say

All approved GLP-1 medications (Ozempic, Wegovy, Mounjaro, Zepbound, Trulicity, Victoza) include labeling cautions about pregnancy use. The labels generally indicate that the drugs should be discontinued at least two months before planned conception, that use during pregnancy is not recommended, and that the drugs may affect glycemic control during pregnancy. These labels are based on animal reproductive toxicology studies, not extensive human pregnancy outcome data.

The animal studies, which are standard for regulatory submission, have shown some effects at higher doses — typically reduced fetal weight and skeletal variations. These findings are considered precautionary rather than conclusive for human risk, which is why the labels recommend against use rather than carrying a contraindication.

What FAERS Actually Is

The FDA Adverse Event Reporting System (FAERS) is a passive reporting database. Healthcare providers, patients, and manufacturers can report suspected adverse events from medications. FAERS is useful for signal detection but has well-known limitations: reports are unverified, causation is not established, reporting rates vary dramatically by drug and time period, and duplicate reports are common.

For a high-profile drug class with tens of millions of prescriptions written, some volume of FAERS reports mentioning pregnancy is mathematically inevitable. The existence of the reports is not evidence of a birth-defect signal. Meaningful analysis requires epidemiological studies using large healthcare databases with denominators, controls, and appropriate statistical methods.

The Published Epidemiological Data

Published studies on human pregnancy outcomes with GLP-1 exposure are limited. A handful of observational analyses have used insurance claims or national health databases in the U.S., Israel, and Scandinavia. These studies generally compare pregnancy outcomes in women with documented GLP-1 exposure (usually before conception or early pregnancy) to comparable control populations. Results have been mixed and have not consistently shown a major birth-defect signal, though the studies are underpowered for rare outcomes and confounded by the underlying conditions (diabetes, obesity) that led to GLP-1 prescription.

The underlying conditions matter. Women with type 2 diabetes or severe obesity have independent increased risks for adverse pregnancy outcomes, including some birth defects. Disentangling medication effects from underlying condition effects requires careful study design, and the available studies have not definitively done so.

What Legitimate Clinical Guidance Says

The American College of Obstetricians and Gynecologists and other specialty societies continue to recommend discontinuing GLP-1 medications prior to planned conception. Patients who become pregnant while on a GLP-1 are typically advised to stop the medication and consult their obstetrician; the published data suggests these pregnancies, on average, do not have dramatically elevated adverse outcome rates relative to the underlying condition-adjusted baseline, but the evidence base is not complete.

Patients planning pregnancy should discuss GLP-1 discontinuation timing with their prescriber. The label-based recommendation of two months before conception reflects the drug's elimination kinetics; longer washouts may be preferred in certain clinical scenarios. For related reporting, see our review of the SELECT trial follow-up and the thyroid cancer black box warning fact check.

Affiliate Disclosure: Some provider links on this page are affiliate links. If you sign up through these links, we may receive compensation at no additional cost to you. This does not influence our editorial content, pricing data, or provider selection.